Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1979 Mar 26;15(2):91-6.
doi: 10.1007/BF00609870.

Relationship between bronchial effects and plasma practolol concentration in man

Clinical Trial

Relationship between bronchial effects and plasma practolol concentration in man

V M Oh et al. Eur J Clin Pharmacol. .

Abstract

A double-blind, balanced and randomised study in 8 healthy volunteers examined the effects of relatively high versus low single doses of practolol on heart rate and ventilation at rest and during standardised exercise. Practolol 1 and 4 mg/kg, a typically non-selective drug propranolol 0.2 mg/kg, and placebo were given intravenously at weekly intervals. Cardiac beta-adrenoceptor blockade was measured by the reduction in exercise heart rate greater than 160 beats/min, and bronchial beta-adrenoceptor blockade by the reduction in exercise peak expiratory flow rate (PEFR) up to 4 h after each treatment. Results were assessed by analysis of co-variance. All three active treatments reduced exercise heart rate markedly, practolol 4 mg/kg causing most reduction. Exercise PEFR was significantly reduced by propranolol 0.2 mg/kg compared with both practolol 1 mg/kg and placebo at all times of measurement, and by practolol 4 mg/kg compared with practolol 1 mg/kg and placebo at most times. Mean plasma concentrations after practolol 4 mg/kg were 3.5 to 4.5 times higher than after 1 mg/kg. Practolol may lose its 'cardioselectivity' and cause airflow obstruction at relatively high plasma concentrations above about 2 microgram/ml.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112-20 - PubMed
    1. Eur J Clin Pharmacol. 1975 Apr 4;8(3-4):175-80 - PubMed
    1. J Clin Invest. 1973 Jan;52(1):48-59 - PubMed
    1. Br Med J. 1970 May 16;2(5706):402-4 - PubMed
    1. Br J Clin Pharmacol. 1978 Feb;5(2):107-20 - PubMed

Publication types

LinkOut - more resources